YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the six months ended June 30, 2021. For the period, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the company's management, the Group's net profit attributable to the parent company for the six months ended June 30, 2021 (without taking into account of convertible bonds) is expected to decrease by approximately 145% to ­155% as compared to the six months ended June 30, 2020.